Atezolizumab,Cabozantinib
Roche
['contact-3', 'congrat', 'rcc,(-irccs),(-srcc),(-urcc)']
#asco23 present the data on contact-3 trial which addresses a major question in the #mrcc #kidneycancer field is there a role of ici re-challenge? answer is no . this study does change my practice in many patients. congrats for the simultaneous 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/ywWAdZmBWt